KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biomarin Pharmaceutical (BMRN) EBIAT (2017 - 2025)

Biomarin Pharmaceutical's EBIAT history spans 16 years, with the latest figure at -$46.6 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT fell 137.28% year-over-year to -$46.6 million, compared with a TTM value of $348.9 million through Dec 2025, down 18.26%, and an annual FY2025 reading of $348.9 million, down 18.26% over the prior year.
  • EBIAT for Q4 2025 was -$46.6 million at Biomarin Pharmaceutical, down from -$30.7 million in the prior quarter.
  • The five-year high for EBIAT was $240.5 million in Q2 2025, with the low at -$57.9 million in Q4 2021.
  • Average EBIAT over 5 years is $51.0 million, with a median of $34.0 million recorded in 2022.
  • Year-over-year, EBIAT tumbled 440.02% in 2021 and then surged 8282.73% in 2023.
  • Tracing BMRN's EBIAT over 5 years: stood at -$57.9 million in 2021, then soared by 99.57% to -$249000.0 in 2022, then surged by 8282.73% to $20.4 million in 2023, then soared by 513.22% to $124.9 million in 2024, then tumbled by 137.28% to -$46.6 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's EBIAT are -$46.6 million (Q4 2025), -$30.7 million (Q3 2025), and $240.5 million (Q2 2025).